Clinical Trials Sponsored by Merck Ltd.

Total 21764 results

University Health Network, Toronto
Merck Frosst Canada Ltd.

Withdrawn

A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo

Pancreatic Adenocarcinoma | Metastatic Disease | Advanced Disease
University of British Columbia
Merck Frosst Canada Ltd.

Completed

Sitagliptin in the Elderly

Type 2 Diabetes

Canada
University Health Network, Toronto
Merck Frosst Canada Ltd.

Completed

A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy (Prostress)

Enlarged Prostate

Canada
St. Joseph's Healthcare Hamilton
Merck Frosst Canada Ltd.

Completed

Blown Nasal Secretion Measurements in Rhinosinusitis: Repeatability and Validity Compared to Nasal Lavage

Rhinosinusitis

Canada
Clinique du Quartier Latin
Merck Frosst Canada Ltd.

Unknown

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

HIV Infections

Canada, Martinique
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.

Terminated

Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

Nausea | Vomiting

Canada
University Health Network, Toronto
Merck Frosst Canada Ltd.

Completed

Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

Hyperlipidemia

Canada
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
Bone Index Finland Ltd
Merck Sharp & Dohme LLC

Completed

Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX

Osteoporosis

Finland
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.

Completed

Risk Factors Contributing to the Development of Microalbuminuria

Microalbuminuria

Canada
University Health Network, Toronto
Merck Frosst Canada Ltd.

Unknown

Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide

Glaucoma

Canada
Children's Mercy Hospital Kansas City
Merck Sharp & Dohme LLC

Completed

Montelukast in the Treatment of Duodenal Eosinophilia

Dyspepsia | Eosinophilic Gastroenteritis

United States
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Canadian Urology Research Consortium
Merck Frosst Canada Ltd.; Abbott

Terminated

Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

Osteoporosis
Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France
The Hospital for Sick Children
Merck Frosst Canada Ltd.

Completed

Use of Montelukast to Treat Children With Mild to Moderate Acute Asthma

Asthma, Bronchial

Canada
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Spain, France, Italy, Japan, Russian Federation, United Kingdom
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Solid Tumors

Japan
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
Zai Lab (Hong Kong), Ltd.
Merck Sharp & Dohme LLC; Zai Biopharmaceutical (Shanghai) Co., Ltd.

Recruiting

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Malignant Solid Tumor

United States, Spain
University College, London
Merck Sharp & Dohme LLC; Celleron Therapeutics Ltd.

Withdrawn

A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PLACARD)

Diffuse Large B Cell Lymphoma
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.; Schering-Plough

Terminated

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

Hypercholesterolemia

Canada
Shenzhen Ionova Life Sciences Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Cancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, Solid

United States
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
Jichi Medical University
Merck Sharp & Dohme LLC; Satt Co.,Ltd

Completed

To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia (Super1)

Hypertension | Insomnia

Japan
National Services for Health Improvement Ltd
Merck Sharp & Dohme LLC

Completed

Glasgow Asthma and Allergy Study (GLAAS)

Asthma | Allergy

United Kingdom
Hamilton Health Sciences Corporation
Merck Frosst Canada Ltd.

Completed

A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients

Hip Fracture
Canadian Heart Research Centre
Merck Frosst Canada Ltd.; Schering-Plough

Completed

Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE ) (GUIDE)

Cardiovascular Diseases

Canada
Keio University
Merck Sharp & Dohme LLC; Ohara Pharmaceutical Co., Ltd.

Recruiting

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Melanoma

Japan
EMD Serono
Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Terminated

Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (DreaMS)

Multiple Sclerosis

United States, Belgium, Canada, Czech Republic, Germany, Japan, Poland, Russian Federation, Spain, Ukraine, Greece
University Hospital Freiburg
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (VBDD)

Multiple Myeloma in Relapse

Germany
University of British Columbia
Merck Frosst Canada Ltd.; Health Canada

Terminated

The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

Hematuria | Hematospermia

Canada
Osaka University
Merck Sharp & Dohme LLC; ISHIHARA SANGYO KAISHA,LTD. Japan

Unknown

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Advanced Melanoma

Japan
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Kft., Hungary

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary (ECOS HUN)

Growth Disorders

Hungary
Merck KGaA, Darmstadt, Germany
Merck A.E., Greece

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece (ECOS GRE)

Growth Disorders

Greece
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Merck KGaA, Darmstadt, Germany
Merck A.E., Greece

Completed

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Multiple Sclerosis, Relapsing-Remitting

Greece
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Terminated

A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Infertility | Ovulation Induction

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Terminated

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Infertility | Ovulation Induction

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Fibromyalgia

Spain
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
Sir Mortimer B. Davis - Jewish General Hospital
Merck Frosst Canada Ltd.

Terminated

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

Pre-diabetes | Pre-hypertension

Canada
University of Saskatchewan
Merck Frosst Canada Ltd.; Ministry of Health, Saskatchewan

Unknown

Community Pharmacy Assisting in Total Cardiovascular Health (CPATCH)

Adherence | Statin Therapy

Canada
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone (SGA)

Infant, Small for Gestational Age

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain (ECOS ESP)

Growth Disorders

Spain
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Withdrawn

Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets

Diabetes Mellitus Type 2
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands

Terminated

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) (MESTRE-MS)

Multiple Sclerosis

Germany
Merck KGaA, Darmstadt, Germany
Merck S.A. Columbia

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia (ECOS COL)

Growth Disorders

Colombia

Clinical Trials Sponsored by Merck Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations